{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Ph%2B+ALL&page=2",
    "query": {
      "condition": "Ph+ ALL",
      "page": 2
    },
    "page_size": 10
  },
  "pagination": {
    "page": 2,
    "page_size": 10,
    "total_count": 10,
    "total_pages": 1,
    "next_page_url": null,
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Ph%2B+ALL&page=1&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-05-22T03:08:05.898Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT00923247",
      "title": "A Targeted Phase I/II Trial of ZD6474 (Vandetanib; ZACTIMA) Plus the Proteasome Inhibitor, Bortezomib (Velcade ), in Adults With Solid Tumors With a Focus on Hereditary or Sporadic, Locally Advanced or Metastatic Medullary Thyroid Cancer (MTC)",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Medullary Thyroid Carcinoma"
      ],
      "interventions": [
        {
          "name": "Bortezomib",
          "type": "DRUG"
        },
        {
          "name": "Vandetanib",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "80 Years",
        "sex": "ALL",
        "summary": "18 Years to 80 Years"
      },
      "enrollment_count": 22,
      "start_date": "2009-02-19",
      "completion_date": "2016-12-09",
      "has_results": true,
      "last_update_posted_date": "2018-11-29",
      "last_synced_at": "2026-05-22T03:08:05.898Z",
      "location_count": 1,
      "location_summary": "Bethesda, Maryland",
      "locations": [
        {
          "city": "Bethesda",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00923247"
    },
    {
      "nct_id": "NCT00597493",
      "title": "Ph. 2 Sorafenib + Protracted Temozolomide in Recurrent GBM",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Recurrent Glioblastoma Multiforme"
      ],
      "interventions": [
        {
          "name": "Sorafenib and Temozolomide",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Duke University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 32,
      "start_date": "2007-09",
      "completion_date": "2010-12",
      "has_results": true,
      "last_update_posted_date": "2013-06-24",
      "last_synced_at": "2026-05-22T03:08:05.898Z",
      "location_count": 1,
      "location_summary": "Durham, North Carolina",
      "locations": [
        {
          "city": "Durham",
          "state": "North Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00597493"
    },
    {
      "nct_id": "NCT02484430",
      "title": "Sapanisertib in Treating Patients With Relapsed and/or Refractory Acute Lymphoblastic Leukemia",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "B Acute Lymphoblastic Leukemia",
        "B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1",
        "B Acute Lymphoblastic Leukemia, Philadelphia Chromosome Negative",
        "Recurrent Adult Acute Lymphoblastic Leukemia",
        "Refractory Adult Acute Lymphoblastic Leukemia",
        "T Acute Lymphoblastic Leukemia"
      ],
      "interventions": [
        {
          "name": "Laboratory Biomarker Analysis",
          "type": "OTHER"
        },
        {
          "name": "Pharmacological Study",
          "type": "OTHER"
        },
        {
          "name": "Sapanisertib",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "OTHER",
        "DRUG"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 16,
      "start_date": "2017-04-06",
      "completion_date": "2024-03-05",
      "has_results": true,
      "last_update_posted_date": "2025-03-03",
      "last_synced_at": "2026-05-22T03:08:05.898Z",
      "location_count": 14,
      "location_summary": "Phoenix, Arizona • Scottsdale, Arizona • Duarte, California + 10 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Scottsdale",
          "state": "Arizona"
        },
        {
          "city": "Duarte",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02484430"
    },
    {
      "nct_id": "NCT03943823",
      "title": "Postmenopausal Pessary Users: Estrogen Versus Trimosan",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Vaginosis",
        "Vaginosis, Bacterial",
        "Vaginal Discharge"
      ],
      "interventions": [
        {
          "name": "Estrogen vaginal cream",
          "type": "DRUG"
        },
        {
          "name": "Trimo-San vaginal gel",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "The University of Texas Health Science Center, Houston",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "40 Years",
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "40 Years and older · Female only"
      },
      "enrollment_count": 4,
      "start_date": "2019-05-07",
      "completion_date": "2021-04-08",
      "has_results": true,
      "last_update_posted_date": "2023-03-08",
      "last_synced_at": "2026-05-22T03:08:05.898Z",
      "location_count": 1,
      "location_summary": "Houston, Texas",
      "locations": [
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03943823"
    },
    {
      "nct_id": "NCT03037580",
      "title": "Oral Treprostinil in Subjects With Pulmonary Hypertension Associated With Heart Failure With Preserved Ejection Fraction",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Pulmonary Hypertension",
        "Heart Failure With Preserved Ejection Fraction"
      ],
      "interventions": [
        {
          "name": "Oral treprostinil",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "United Therapeutics",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "85 Years",
        "sex": "ALL",
        "summary": "18 Years to 85 Years"
      },
      "enrollment_count": 84,
      "start_date": "2017-08-15",
      "completion_date": "2019-12-03",
      "has_results": true,
      "last_update_posted_date": "2020-11-10",
      "last_synced_at": "2026-05-22T03:08:05.898Z",
      "location_count": 82,
      "location_summary": "Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 66 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03037580"
    },
    {
      "nct_id": "NCT04260022",
      "title": "Study of HQP1351 in Subjects With Refractory CML and Ph+ ALL",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Leukemia, Myeloid, Chronic",
        "Myeloid Leukemia",
        "Chronic Myeloid Leukemia",
        "Philadelphia Positive Acute Lymphoblastic Leukemia",
        "B Cell Precursor Type Acute Leukemia"
      ],
      "interventions": [
        {
          "name": "Ascentage Pharma HQP1351 bioavailable inhibitor",
          "type": "DRUG"
        },
        {
          "name": "Blinatumomab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Ascentage Pharma Group Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 242,
      "start_date": "2020-01-09",
      "completion_date": "2030-03-31",
      "has_results": false,
      "last_update_posted_date": "2025-11-05",
      "last_synced_at": "2026-05-22T03:08:05.898Z",
      "location_count": 8,
      "location_summary": "Birmingham, Alabama • Duarte, California • Atlanta, Georgia + 5 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Duarte",
          "state": "California"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Augusta",
          "state": "Georgia"
        },
        {
          "city": "Baltimore",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04260022"
    },
    {
      "nct_id": "NCT00498966",
      "title": "Ph II Study of Perifosine for Patients With Carcinoma of the Kidney",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Kidney Cancer"
      ],
      "interventions": [
        {
          "name": "Perifosine",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "AEterna Zentaris",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 50,
      "start_date": "2007-07",
      "completion_date": "2011-10",
      "has_results": false,
      "last_update_posted_date": "2018-02-05",
      "last_synced_at": "2026-05-22T03:08:05.898Z",
      "location_count": 3,
      "location_summary": "Louisville, Kentucky • Morristown, New Jersey • Armonk, New York",
      "locations": [
        {
          "city": "Louisville",
          "state": "Kentucky"
        },
        {
          "city": "Morristown",
          "state": "New Jersey"
        },
        {
          "city": "Armonk",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00498966"
    },
    {
      "nct_id": "NCT00678652",
      "title": "Phase 1 Safety and Immunogenicity of Meningococcal Vaccine",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Meningococcal Infection, Group B"
      ],
      "interventions": [
        {
          "name": "10 μg Group B Meningococcal 8570 HOPS-G NOMV Vaccine",
          "type": "BIOLOGICAL"
        },
        {
          "name": "25 μg Group B Meningococcal 8570 HOPS-G NOMV Vaccine",
          "type": "BIOLOGICAL"
        },
        {
          "name": "50 μg Group B Meningococcal 8570 HOPS-G NOMV Vaccine",
          "type": "BIOLOGICAL"
        },
        {
          "name": "75 μg Group B Meningococcal 8570 HOPS-G NOMV Vaccine",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "U.S. Army Medical Research and Development Command",
      "sponsor_class": "FED",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "45 Years",
        "sex": "ALL",
        "summary": "18 Years to 45 Years"
      },
      "enrollment_count": 36,
      "start_date": "2008-04",
      "completion_date": "2009-08",
      "has_results": true,
      "last_update_posted_date": "2017-12-18",
      "last_synced_at": "2026-05-22T03:08:05.898Z",
      "location_count": 1,
      "location_summary": "Silver Spring, Maryland",
      "locations": [
        {
          "city": "Silver Spring",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00678652"
    },
    {
      "nct_id": "NCT01561729",
      "title": "Nasogastric/Orogastric Tube Placement Verification Study Using RightSpot pH Indicator to Verify Gastric Acidity",
      "overall_status": "UNKNOWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Small Bowel Obstruction",
        "Gastrointestinal Hemorrhage"
      ],
      "interventions": [
        {
          "name": "RightSpot pH Indicator",
          "type": "DEVICE"
        },
        {
          "name": "Chest radiograph",
          "type": "RADIATION"
        }
      ],
      "intervention_types": [
        "DEVICE",
        "RADIATION"
      ],
      "sponsor": "RightBio Metrics",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 30,
      "start_date": "2012-01",
      "completion_date": "2014-12",
      "has_results": false,
      "last_update_posted_date": "2014-11-04",
      "last_synced_at": "2026-05-22T03:08:05.898Z",
      "location_count": 1,
      "location_summary": "Tampa, Florida",
      "locations": [
        {
          "city": "Tampa",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01561729"
    },
    {
      "nct_id": "NCT00734864",
      "title": "Ph. I Dasatinib/Protracted Temozolomide in Recurrent Malignant Glioma",
      "overall_status": "WITHDRAWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Glioblastoma Multiforme",
        "Gliosarcoma",
        "Anaplastic Astrocytoma",
        "Anaplastic Oligodendroglioma",
        "Glioma"
      ],
      "interventions": [
        {
          "name": "enzyme-inducing anti-epileptic drugs",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Annick Desjardins",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 0,
      "start_date": "2009-06",
      "completion_date": "2012-06",
      "has_results": false,
      "last_update_posted_date": "2012-11-21",
      "last_synced_at": "2026-05-22T03:08:05.898Z",
      "location_count": 1,
      "location_summary": "Durham, North Carolina",
      "locations": [
        {
          "city": "Durham",
          "state": "North Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00734864"
    }
  ]
}